类风湿关节炎（RA）是一种以关节组织慢性炎症病变为主要特征的致残性疾病，其病因复杂，临床尚无法彻底根治，如何早期发现和诊断RA，并在病变的早期阶段进行药物干预和治疗，是防控RA的关键。本课题针对RA早期发现和诊疗难的迫切需求，基于介导炎性反应的细胞黏附分子选择素的高表达，在高亲和结合选择素的树枝状甘油硫酸酯dPGS上构建具有光磁复合性能的新型分子探针，通过活体动物模型和光磁成像，考察RA炎症发生、发展过程中的特性；通过巧妙设计连接塞来昔布，实现对抗炎药物的靶向递送，并通过不同炎性细胞、动物模型和光磁成像研究，明确新型分子探针诊疗RA的特异性和敏感性。本项目是在我们良好的前期工作基础上，利用多模态成像技术的优势互补，验证新型分子探针在不同RA模型中的有效性，有望同时实现对RA的早期发现和诊断，实时成像和预后评价，为研究和开发新型的靶向抗炎药物和诊疗一体化药物提供理论基础和科学依据。

Rheumatoid arthritis (RA) is a long lasting autoimmune disorder and disabling disease with the main character of chronic inflammatory lesions that primarily affects joints. While the cause of rheumatoid arthritis is not clear, it is believed to involve a combination of genetic and environmental factors. Treatment of RA is a challenge in the clinic. How to detect and diagnosis of RA as well as the followed therapy in its early stage are the key for the combat against this disease. It’s urgent needed to develop an ideal tool for the detection and monitoring such progress specially for the lack of efficient real time method for RA. In this project, we for the first time design a novel multimodal probe for simultaneous optical imaging and MR imaging and treatment of RA. The biomarker is seletin, which is highly expressed in the inflammation sites. Based on the established dendritic polyglycerorls (dPGS), which is highly biocompatible and presents the function for multivalent selectin binding and the inhibition of complement activation, we construct the novel optical/MR probe as the imaging and therapeutical agent. With an ingenious design of connection, celecoxib is conjugated to form the theranostic probe, which can be delivered and released in the inflammation site. We examine the probe with various RA cell and animal in vitro. The biological activities are evaluated for their specificities and sensitivenesss for the detection and imaging for RA. Further mechanism experiments are explored to understand why the novel probe can be applied for the detection and therapy of RA. These results of this project will provide a novel tool for real time imaging and therapeutically evaluation of RA, and open an avenue for the development of novel antiflammation drug and theranostic drug.